HUMACYTE INC (HUMA) Fundamental Analysis & Valuation

NASDAQ:HUMA • US44486Q1031

Current stock price

0.8536 USD
+0.01 (+1.4%)
At close:
0.8382 USD
-0.02 (-1.8%)
After Hours:

This HUMA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. HUMA Profitability Analysis

1.1 Basic Checks

  • In the past year HUMA has reported negative net income.
  • HUMA had a negative operating cash flow in the past year.
  • HUMA had negative earnings in each of the past 5 years.
  • HUMA had a negative operating cash flow in each of the past 5 years.
HUMA Yearly Net Income VS EBIT VS OCF VS FCFHUMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M

1.2 Ratios

  • HUMA's Return On Assets of -35.09% is in line compared to the rest of the industry. HUMA outperforms 59.61% of its industry peers.
  • HUMA has a worse Return On Equity (-1313.38%) than 82.33% of its industry peers.
Industry RankSector Rank
ROA -35.09%
ROE -1313.38%
ROIC N/A
ROA(3y)-76.52%
ROA(5y)-48.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HUMA Yearly ROA, ROE, ROICHUMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

1.3 Margins

  • HUMA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HUMA Yearly Profit, Operating, Gross MarginsHUMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. HUMA Health Analysis

2.1 Basic Checks

  • HUMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for HUMA has been increased compared to 1 year ago.
  • Compared to 5 years ago, HUMA has more shares outstanding
  • The debt/assets ratio for HUMA has been reduced compared to a year ago.
HUMA Yearly Shares OutstandingHUMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
HUMA Yearly Total Debt VS Total AssetsHUMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • HUMA has an Altman-Z score of -10.29. This is a bad value and indicates that HUMA is not financially healthy and even has some risk of bankruptcy.
  • HUMA has a Altman-Z score of -10.29. This is in the lower half of the industry: HUMA underperforms 73.59% of its industry peers.
  • A Debt/Equity ratio of 20.08 is on the high side and indicates that HUMA has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 20.08, HUMA is doing worse than 84.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 20.08
Debt/FCF N/A
Altman-Z -10.29
ROIC/WACCN/A
WACC9.08%
HUMA Yearly LT Debt VS Equity VS FCFHUMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 3.69 indicates that HUMA has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.69, HUMA perfoms like the industry average, outperforming 45.05% of the companies in the same industry.
  • A Quick Ratio of 2.95 indicates that HUMA has no problem at all paying its short term obligations.
  • The Quick ratio of HUMA (2.95) is worse than 61.94% of its industry peers.
Industry RankSector Rank
Current Ratio 3.69
Quick Ratio 2.95
HUMA Yearly Current Assets VS Current LiabilitesHUMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. HUMA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 84.13% over the past year.
  • HUMA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.46% yearly.
EPS 1Y (TTM)84.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)N/A
Revenue growth 3Y9.09%
Revenue growth 5Y6.46%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, HUMA will show a very strong growth in Earnings Per Share. The EPS will grow by 83.79% on average per year.
  • The Revenue is expected to grow by 207.79% on average over the next years. This is a very strong growth
EPS Next Y-115.05%
EPS Next 2Y-28.25%
EPS Next 3Y72.82%
EPS Next 5Y83.79%
Revenue Next Year284.8%
Revenue Next 2Y266.15%
Revenue Next 3Y258.89%
Revenue Next 5Y207.79%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HUMA Yearly Revenue VS EstimatesHUMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
HUMA Yearly EPS VS EstimatesHUMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. HUMA Valuation Analysis

4.1 Price/Earnings Ratio

  • HUMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year HUMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HUMA Price Earnings VS Forward Price EarningsHUMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HUMA Per share dataHUMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HUMA's earnings are expected to grow with 72.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.25%
EPS Next 3Y72.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HUMA Dividend Analysis

5.1 Amount

  • No dividends for HUMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HUMA Fundamentals: All Metrics, Ratios and Statistics

HUMACYTE INC

NASDAQ:HUMA (5/1/2026, 4:10:07 PM)

After market: 0.8382 -0.02 (-1.8%)

0.8536

+0.01 (+1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-27
Earnings (Next)05-08
Inst Owners25.27%
Inst Owner Change0.23%
Ins Owners5.05%
Ins Owner Change2.24%
Market Cap189.52M
Revenue(TTM)2.04M
Net Income(TTM)-40.83M
Analysts81.54
Price Target5.17 (505.67%)
Short Float %23.57%
Short Ratio6.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.55%
Min EPS beat(2)3.2%
Max EPS beat(2)31.89%
EPS beat(4)3
Avg EPS beat(4)58.51%
Min EPS beat(4)-45.54%
Max EPS beat(4)244.48%
EPS beat(8)4
Avg EPS beat(8)14.63%
EPS beat(12)7
Avg EPS beat(12)4.8%
EPS beat(16)10
Avg EPS beat(16)24.62%
Revenue beat(2)0
Avg Revenue beat(2)-42.94%
Min Revenue beat(2)-65.91%
Max Revenue beat(2)-19.96%
Revenue beat(4)0
Avg Revenue beat(4)-47.45%
Min Revenue beat(4)-70.58%
Max Revenue beat(4)-19.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-35.45%
PT rev (3m)-35.45%
EPS NQ rev (1m)2.03%
EPS NQ rev (3m)2.03%
EPS NY rev (1m)5.6%
EPS NY rev (3m)6.64%
Revenue NQ rev (1m)-63.05%
Revenue NQ rev (3m)-63.05%
Revenue NY rev (1m)-53.7%
Revenue NY rev (3m)-53.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 92.99
P/FCF N/A
P/OCF N/A
P/B 60.96
P/tB 60.96
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.01
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -35.09%
ROE -1313.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.52%
ROA(5y)-48.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 20.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.04%
Cap/Sales 43.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.69
Quick Ratio 2.95
Altman-Z -10.29
F-Score5
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)21.15%
Cap/Depr(5y)15.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-115.05%
EPS Next 2Y-28.25%
EPS Next 3Y72.82%
EPS Next 5Y83.79%
Revenue 1Y (TTM)N/A
Revenue growth 3Y9.09%
Revenue growth 5Y6.46%
Sales Q2Q%N/A
Revenue Next Year284.8%
Revenue Next 2Y266.15%
Revenue Next 3Y258.89%
Revenue Next 5Y207.79%
EBIT growth 1Y5.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.7%
EBIT Next 3Y38.81%
EBIT Next 5Y32.47%
FCF growth 1Y-6.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.05%
OCF growth 3YN/A
OCF growth 5YN/A

HUMACYTE INC / HUMA Fundamental Analysis FAQ

What is the fundamental rating for HUMA stock?

ChartMill assigns a fundamental rating of 2 / 10 to HUMA.


What is the valuation status for HUMA stock?

ChartMill assigns a valuation rating of 1 / 10 to HUMACYTE INC (HUMA). This can be considered as Overvalued.


What is the profitability of HUMA stock?

HUMACYTE INC (HUMA) has a profitability rating of 0 / 10.


What is the financial health of HUMACYTE INC (HUMA) stock?

The financial health rating of HUMACYTE INC (HUMA) is 3 / 10.


What is the expected EPS growth for HUMACYTE INC (HUMA) stock?

The Earnings per Share (EPS) of HUMACYTE INC (HUMA) is expected to decline by -115.05% in the next year.